House Speaker Paul Ryan (R-WI) yesterday discussed a potential compromise on the Creating and Restoring Equal Access to Equivalent Samples Act (S. 974/H.R. 2212), as part of congressional action to address high drug prices. “We’re working between the Commerce Committee and the Judiciary Committee on a compromise on what we call CREATES, which is getting the generics online faster after patents have expired, so I think there are things we can do in that area,” Ryan said, according to published reports, during an event hosted by a Washington, D.C. law firm. Among other provisions, the legislation would allow a generic drug manufacturer facing a sample-sharing delay tactic to bring an action in federal court for injunctive relief and allow a judge to award damages to deter future delaying conduct. Earlier this year, AHA and more than 40 organizations urged Congress to pass the legislation calling it “a narrowly targeted, bipartisan, pro-competition and market-based solution to these abuses that cost patients, job-creators and taxpayers billions of dollars each year.”
AHA Releases New Report that Shows Continued Rising Drug Prices and Drug Shortages are Disrupting Patient Care, Hospital Budgets
Continued rising drug prices, as well as shortages for many critical medications, are disrupting patient care and forcing hospitals to delay infrastructure and…
The AHA and the Federation of American Hospitals today urged Congress to oppose any legislation that would repeal current law limiting self-referral to…
A coalition of 40 health care and public health organizations, including the AHA, today urged the Senate to quickly pass the Pandemic and All-Hazards…
We’re 11 days into 2019 … we’ve returned to a divided government …and the partial government shutdown continues.
Insights and Analysis
Also in this weekly roundup of health news: AHA president and CEO Rick Pollack speaks to HealthLeaders about the association’s year ahead; digital health…
The House of Representatives last night passed legislation (H.R. 269) that includes the Pandemic and All-Hazards Preparedness and Advancing Innovation Act.